RB1CC1 and cancer: The combined evaluation of RB1CC1, RB1 and p53 predicted a longer DSS after more than 5 years in the cases with non-triple-negative cancers; i.e., no cancer-specific death was recorded among RB1CC1(+)/RB1(+)/p53nor patients in the later follow-up periods (>5 years).